Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech firesales -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (2688)	7/27/2010 6:00:01 PM
From: Ian@SI	Respond to of 3661

Dew, I'm not trying to say that the connection is rational, based on fact or, in any way justifies the selloff today. However, there's lots of room to misinterpret the WSJ statement, "Broadly, the results showed ticagrelor reduced the combination of heart attacks, strokes and death from cardiovascular causes by 16%, compared with Plavix, after being treated for a year. All patients received aspirin.". Rather, I would agree with Tuck. This is an opportunity to top up any positions in MNTA at a discount. If Brilanta is approved(recommended by AC) on Wednesday, then there could be an even better opportunity on Thursday.